Elliot Norry is Chief Medical Officer at Adaptimmune Therapeutics PLC (ADAP). They have made 14 open-market trades across 1 company since 2020, most recently 2025-01-17.
CIK 0001798117
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADAP | 7,510 | $412 |
Shares reported on the most recent Form 4, priced at the 2025-01-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADAP | SELL | 2025-01-17 | 2025-01-17 | $0.58 | $3K | +7.0% | +2.3% | -58.1% |
| ADAP | SELL | 2025-01-13 | 2025-01-15 | $0.58 | $13K | -0.5% | -2.5% | -57.9% |
| ADAP | SELL | 2024-01-16 | 2024-01-17 | $0.68 | $14K | +10.3% | +66.8% | +43.1% |
| ADAP | SELL | 2024-01-11 | 2024-01-12 | $0.85 | $10K | -6.7% | +53.2% | +63.3% |
| ADAP | SELL | 2023-01-17 | 2023-01-17 | $1.86 | $4K | +2.9% | -2.3% | -20.6% |
| ADAP | SELL | 2023-01-11 | 2023-01-12 | $1.72 | $19K | +2.2% | -13.9% | -33.9% |
| ADAP | SELL | 2023-01-04 | 2023-01-04 | $1.69 | $1K | -3.3% | -8.3% | -43.1% |
| ADAP | SELL | 2022-01-18 | 2022-01-18 | $3.19 | $7K | -12.7% | -2.3% | -40.1% |
| ADAP | SELL | 2022-01-11 | 2022-01-13 | $3.56 | $16K | -15.8% | -7.5% | -41.5% |
| ADAP | SELL | 2022-01-04 | 2022-01-05 | $4.06 | $3K | -14.3% | -21.3% | -39.2% |
| ADAP | SELL | 2021-01-19 | 2021-01-19 | $5.67 | $12K | -6.8% | +2.0% | -20.1% |
| ADAP | SELL | 2021-01-12 | 2021-01-12 | $6.15 | $5K | -1.4% | +13.7% | -14.8% |
| ADAP | SELL | 2021-01-04 | 2021-01-05 | $5.33 | $5K | +1.3% | +3.5% | -0.6% |
| ADAP | SELL | 2020-01-14 | 2020-01-15 | $5.13 | $5K | -5.3% | -3.8% | -17.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.